BOOST Pharma ApS: Financial statements 2023
CVR: 41120495
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
BOOST Pharma ApS (CVR 41120495) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -1,529,771 and a net result of DKK -2,753,145 compared with DKK -4,197,998 the year before. Equity in the 2023 report amounted to DKK -9,198,682. The company had 1 employee in the financial year.
- Gross Profit
- DKK -1,529,771
- Profit/Loss
- DKK -2,753,145
- Equity
- DKK -9,198,682
- Total Assets
- DKK 2,216,746
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -1.5 mio. | -2.8 mio. | -9.2 mio. | 1 |
| 2022 | - | -3.5 mio. | -4.2 mio. | -6.4 mio. | 1 |
| 2021 | - | -1.3 mio. | -2.2 mio. | -2.2 mio. | 1 |
| 2020 | - | -21 t. | -63 t. | -23 t. | - |
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
BOOST Pharma ApS has published its annual report for 2022. Gross profit came to DKK -3,499,684, and the net result was DKK -4,197,998.
About BOOST Pharma ApS
BOOST Pharma ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2020. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Hans Thalsgård Schambye. The company is owned by BOOST Pharma AB. According to the 2025 annual report, the company had an average of 2 employees. In 2025, the company reported a gross profit of DKK -7,557,572 and a net result of DKK -9,243,488 compared with DKK -4,259,583 the year before. Equity in the 2025 report amounted to DKK -11,850,535.